A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib in Patients With Relapsed of Refractory Multiple Myeloma

Trial Profile

A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib in Patients With Relapsed of Refractory Multiple Myeloma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Trametinib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Apr 2016 Status changed from recruiting to withdrawn prior to enrolment a the PI left institution, according to ClinicalTrials.gov record.
    • 27 Jul 2015 Planned End Date changed from 1 Jun 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 27 Jul 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top